Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

VentriPoint Diagnostics Ltd. (V:VPT)

Business Focus: Advanced Medical Equipment & Technology (NEC)

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
Company Contact
Address: 18 Hook Ave, Unit 101
TORONTO ON M6P 1T4
Tel: 1-416-6691001
Website: https://www.ventripoint.com
IR: See website
Key People
George Adams
Executive Chairman of the Board
Alvira Macanovic
President, Chief Executive Officer
Jimmy Jeon
Chief Financial Officer
Business Overview
Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company's Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart's structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system's proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).
Financial Overview
For the nine months ended 30 September 2023, VentriPoint Diagnostics Ltd. revenues decreased 81% to C$8K. Net loss decreased 4% to C$3.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects General and administrative decrease of 18% to C$2.1M (expense), Net Financing Income/Expense - Balancing increase from C$9K (expense) to C$31K (income).
Reporting Currency: Canadian Dollars
Enterprise value: $30.64M as of Sep 30, 2023
Annual revenue (TTM): $0.04M as of Sep 30, 2023
EBITDA (TTM): -$4.73M as of Sep 30, 2023
Net annual income (TTM): -$4.74M as of Sep 30, 2023
Free cash flow (TTM): -$3.86M as of Sep 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 157,182,655 as of Feb 6, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization